The Effectiveness of Inpatient Rehabilitation in Parkinson’s Disease: A Systematic Review of Recent Studies

Elien Steendam-Oldekamp* and Teus van Laar
University of Groningen, Department of Neurology, University Medical Center Groningen, The Netherlands

Accepted 6 March 2024

Abstract

Background: Parkinson’s disease (PD) is a progressive disease, which is associated with the loss of activities of daily living independency. Several rehabilitation options have been studied during the last years, to improve mobility and independency. Objective: This systematic review will focus on inpatient multidisciplinary rehabilitation (MR) in people with Parkinson’s disease (PwPD), based on recent studies from 2020 onwards.

Methods: Search strategy in three databases included: multidisciplinary rehabilitation, Parkinson’s Disease, inpatient rehabilitation, motor-, functional- and cognitive performance, cost-effectiveness, Quality of Life, and medication changes/Levodopa equivalent daily doses.

Results: Twenty-two studies were included, consisting of 13 studies dealing with inpatient MR and 9 studies on inpatient non-MR interventions. Inpatient PD multidisciplinary rehabilitation proved to be effective, as well as non-MR rehabilitation.

Conclusions: This review confirms the efficacy of inpatient MR and non-MR in PD, but is skeptical about the past and current study designs. New study designs, including new physical training methods, more attention to medication and costs, new biomarkers, artificial intelligence, and the use of wearables, will hopefully change rehabilitation trials in PwPD in the future.

Keywords: Parkinson’s disease, multidisciplinary treatment, inpatient rehabilitation, drug optimization

INTRODUCTION

Background

Parkinson’s disease (PD) is a complex neurodegenerative disorder, which leads to many motor- and non-motor problems, including neuropsychiatric-, sleep-, and autonomic signs and symptoms [1–3]. Severe symptoms in one domain, or combinations of symptoms in several domains impair activities of daily living (ADL), as is the case in people with PD (PwPD), showing increasing ADL deficits over time, which results in an increase of the burden on caregivers. Finally, this may result in hospital admission or admission to one of the Parkinson rehabilitation programs, in order to improve ADL independency and extending the period of being able to live at home. This review will focus on the effectiveness of inpatient PD rehabilitation programs and will summarize the set-up and outcomes of recent studies in this field,
including long-term- and cost-effectiveness data, if available. It is quite important to get a clear understanding of these issues, because the overall numbers of PwPD are increasing, globally from 6.2 million at this moment, to 12.9 million PwPD in 2040 [4, 5]. As a result, health care costs will rise exponentially. Institutional care is one of the most important drivers of overall costs related to PD, representing 67% of the direct costs [6–9]. A nationwide retrospective cohort study initiated from University of Pennsylvania identified 469,055 PwPD who received Medicare benefits in 2002. Nearly 25% (more than 100,000 in total) resided in a long-term care facility. Women with PD had greater odds of nursing facility residence (adjusted odds ratio (AOR) 1.34, 95% confidence interval (CI) 1.30–1.38) compared to men. A multicenter study in Sydney described that 48% of the PwPD were finally admitted in a nursing home [10–12]. Therefore, efficient PD rehabilitation is a very important instrument to improve ADL, hopefully leading to postponement of definite nursing home admission. Without proper cost-effectiveness evidence, it will be difficult for policymakers, insurance companies, clinicians, and PwPD and their caregivers to identify the value of these rehabilitation interventions [13].

The aim of this review is to provide an overview of all studies on inpatient rehabilitation of PwPD, performed between 2020 and 2023, focusing on outcomes related to motor-, functional- and cognitive performance, cost-effectiveness, quality of life (QoL), and medication changes. We will grade the available evidence, identifying existing gaps in knowledge and making recommendations for the current inpatient rehabilitation programs of PwPD, finally suggesting which future studies should be performed to guide this field.

Overview of PD inpatient rehabilitation data before 2020

Different rehabilitation program models already exist for PwPD, including inpatient multidisciplinary rehabilitation, integrated interdisciplinary models in an outpatient setting, community-based interventional programs or a combination of these concepts. This review will focus on inpatient rehabilitation programs. Various inpatient multidisciplinary models were developed during the last decade, including the German PD-Multimodel Complex Treatment (MCT) model [14–17], the Italian Multidisciplinary Intensive Rehabilitation Treatment concept [18–22], the Dutch inpatient rehabilitation program at Parkinson Expertise Centers (Point for Parkinson), and the Hamburg Parkinson Day-Clinic, indicated for complex PwPD patients, with in- and outpatient care and the use of sophisticated treatment strategies [23]. Most of the models use serial evaluations, followed by an overall care plan, generated by the expertise team on each necessary discipline. Not all the models pay attention to medication (personalized medicine) but are mainly focusing on physiotherapy and physical exercise for PwPD with mild-to-moderate disability Hoehn&Yahr (H&Y) stage 1-3. Also little attention is paid to people with advanced PD (including cognitive impairment), to overall costs and long-term effects. In addition to these existing models, several physical exercise programs (e.g., dancing, climbing, music therapy), or adjunct tools (e.g., virtual reality and robotics), are offered as add-on treatments [24–32]. A Cochrane report on the effect of physical exercise for PwPD, including 156 randomized controlled trials (RCTs) with a total of 7,939 participants, concluded that most types of physical exercise improved the movement patterns and quality of life, whereas the efficacy of these types of physical exercise did not show significant differences. This large Cochrane meta-analysis also concluded that larger, well-conducted studies are needed to increase confidence in the evidence, also including people with advanced disease and cognitive impairments, to be able to generalize the findings to a broader range of PwPD [33]. In addition, there is also a lack of robust evidence for interventions to reduce hospitalization [34] and nursing home admission [35–38]. The same applies to the adjunct tools and techniques with small sample sizes, high risk of bias and no long-term evidence [39–45].

METHODS

Search methods

A search was carried out in the following scientific database: PubMed, Embase, Cochrane library (Fig. 1). Review was carried out following the PRISMA guidelines. Search strategy included: multidisciplinary or interdisciplinary rehabilitation, Parkinson’s Disease, inpatient-outpatient: In PubMed, EMBASE and Cochrane library: Search MeSH terms: ‘rehabilitation AND Parkinson’, ‘inpatient AND rehabilitation AND Parkinson’, ‘inpatient AND rehabilitation AND Parkinson’s disease’ and
Fig. 1. Flowchart of the literature and search strategy (Search MeSH terms: ‘inpatient AND rehabilitation’ ‘inpatient AND rehabilitation AND Parkinson/Parkinson’s disease’).

Table 1

<table>
<thead>
<tr>
<th>Item</th>
<th>Inclusion of:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design</td>
<td>Randomized controlled trials and non-randomized controlled trials as crossover trials, pre-post test with no control, prospective and retrospective trials</td>
</tr>
<tr>
<td>Participants</td>
<td>People with Parkinson’s disease n&gt;10, healthy controls</td>
</tr>
<tr>
<td>Intervention</td>
<td>Inpatient rehabilitation</td>
</tr>
<tr>
<td>Comparisons</td>
<td>Usual care T0 and T1, short-term, long-term</td>
</tr>
<tr>
<td>Outcome measures</td>
<td>Outcomes related to motor-, functional- and cognitive performance, cost-effectiveness, Quality of Life (QoL) and medication changes</td>
</tr>
</tbody>
</table>

‘inpatient AND multidisciplinary rehabilitation AND Parkinson’.

Selection criteria

Inclusion criteria. The inclusion criteria are summarized in Table 1. Only full text publications in scientific journals (excluding abstracts and posters), written in English were selected for this review.

A classical meta-analysis could not be performed, because of the clinical heterogeneity of the study groups, and the variability in endpoints. All study characteristics are summarized in Table 1. Assessment of each study was done by the first author (in- and exclusion) and was verified by the last author. The quality of evidence of all included studies was rated independently by both authors, and disagreements between the authors were discussed, and solved by consensus, according to the GRADE system [46]. Reasons for downgrading the overall rating were based on the risk of bias, study design, industry sponsorship, inconsistency of data, indirectness, imprecision, substantial loss to follow-up of participants, and unblinded outcome assessment. We were also aware of the fact that studies with statistically non-significant results may not have been reported or submitted for publication (resp. selective non-reporting bias and publication bias). Reasons for upgrading non-randomized studies consisted of a large magnitude of effect or a low influence of confounding factors.
The multidisciplinary treatment was defined as involving at least two different disciplines, including mostly a neurologist, physiotherapist, occupational therapist, Parkinson’s disease nurse, psychiatrist or (neuro)psychologist, social worker, dietician, and speech therapist. The H&Y rating and disease duration were used to characterize the severity of the disease.

RESULTS

Study characteristics and the quality of evidence

Overall, 22 studies were selected (Table 2), consisting of 13 studies covering inpatient multidisciplinary rehabilitation (MR) and 9 studies dealing with non-MR interventions, but sometimes added to an existing rehabilitation program, which was not the objective of the study. The MR studies consisted of 3 controlled trials, 5 open label prospective trials, and 5 retrospective studies. The non-MR studies consisted of 6 controlled trials, including 4 randomized trials, 2 prospective open label trials, and 1 retrospective trial. This means that the overall quality of study designs of the non-MR interventions group was superior to the MR interventions group. The majority of the studies described the effect of the intervention on motor-, non-motor symptoms and quality of life scores as an endpoint. One study also measured the ability to prevent nursing home admission and one study analyzed the effect of the treatment on neurovascular coupling, a MRI-based endpoint.

The multidisciplinary studies included PwPD with mild-to-moderate disability (H&Y 1-3, mean 2.9) with a disease duration in between 4.7-10.8 years (mean 8.5 years). Only 3 MR studies were controlled trials [47–49]. All of them were non-randomized trials, so including a risk of selection bias. However, 2 controlled MR studies showed a large magnitude of effect on different outcome measurements [47, 48] and have been upgraded from low to moderate quality of evidence for that reason. The other 10 MR studies were either prospective open label (n = 5) or retrospective studies (n = 5). The size of the studies differed significantly, varying between 24 and 591 PwPD, with a smaller number of participants in most prospective studies, and larger populations in the retrospective studies. Most trials reported loss of data and subjects dropping out of the studies. Selection- and recall biases also have affected the results negatively. The duration of the interventions varied from 1 to 8 weeks, with a mean duration of 6.5 weeks in the multidisciplinary studies. Long-term effects were measured in only 5 studies, 8 weeks up to 2 years. Funding was mentioned, if applicable, in all studies and most of the studies were funded by innovation funds, grants or financially supported by governments (12 studies). No studies had been supported by commercial parties.

The 9 non-MR studies consisted of virtual reality and antigravity treadmill training for gait rehabilitation [56], Music-Assisted Treadmill Training [58], body weight-supported overground gait training [64], gravity-supporting exoskeleton training [57], therapeutic climbing [62], exergames integrated in regular rehabilitation [56], and Tai Chi training [59]. The non-MR interventions only studied short-term outcomes. The H&Y scores varied from 1-3 (mean 2.3) with a disease duration between 4.7-10.8 years (mean 6.5 years). The non-MR group included 4 RCTs [56–59], 2 non-randomized controlled studies [60, 61], 2 prospective open label studies [62, 63], and 1 retrospective study [64]. Blinding issues, short duration of the intervention, confounders, inconsistency in measurements and high drop out rate/lost-to-follow up, no intention to treat analysis and small sample size were reasons to downgrade the 4 RCTs from high to moderate quality of evidence. The number of subjects in this group varied between 12 and 41. The duration of the interventions varied from 30 min to 12 weeks (mean 5.4 weeks). All interventions only described short-term effects. Funding was described in all studies, except one who did not mention the funding [63]. One study was funded by a company providing the treatment assessed [58].

Quantitative comparisons of the main domains

Motor improvement

The most common outcome measure in the included studies was the motor score, most frequently assessed by the MDS-UPDRS III (8 studies in the MR group and 4 in the non-MR group, see Tables 2 and
<table>
<thead>
<tr>
<th>Author [ref]</th>
<th>Intervention and duration</th>
<th>Objective</th>
<th>Disease severity - H&amp;Y</th>
<th>Subjects (n)</th>
<th>Study design</th>
<th>Duration follow-up (from baseline)</th>
<th>Primary- and Secondary endpoints</th>
<th>Funding</th>
<th>GRADE (Quality of evidence)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steendam et al. (2023) [47]</td>
<td>6 weeks MR including optimization of pharmacotherapy + outpatient follow-up</td>
<td>ADL improvement and delay of nursing home admission</td>
<td>H&amp;Y</td>
<td>Total n = 43</td>
<td>Prospective, controlled study</td>
<td>2 years</td>
<td>Primary outcomes: - ADL (ALDS) - % living independently at home Secondary outcomes - medication (LEDD) - motor performance (SCOPA-SPES) - cognition (SCOPA-COG) - hallucinations (NPI) - depression (BDI).</td>
<td>UMCG innovation fund and prof. Vander Valk Stichting</td>
<td>⊕⊕⊕ ⃝</td>
</tr>
<tr>
<td>Li et al. (2023) [48]</td>
<td>2 weeks MR</td>
<td>Change in neurovascular coupling on MRI</td>
<td>H&amp;Y</td>
<td>Total n = 61</td>
<td>Prospective controlled study</td>
<td>2 weeks (discharge)</td>
<td>Outcomes: - motor performance (UPDRS-III) - MRI a. resting-state ASL b. resting-state BOLD scan. The global and regional CBF–fALFF correlation</td>
<td>National Natural Science Foundation of China Grants, National Key research and Development Program of China and the Science and Technology Development Fund of Beijing Rehabilitation Hospital, Capital Medical University Grants.</td>
<td>⊕⊕⊕ ⃝</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Author [ref]</th>
<th>Intervention and duration</th>
<th>Objective</th>
<th>Disease severity -H&amp;Y -DD (y)</th>
<th>Subjects (n)</th>
<th>Duration follow-up (from baseline)</th>
<th>Primary- and Secondary endpoints</th>
<th>Study design</th>
<th>Funding</th>
<th>GRADE (Quality of evidence)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wagner et al. (2022)</td>
<td>1. 3 weeks MR 2. 9 months physiotherapy (App-based) 3 times/week, + outpatient follow-up</td>
<td>Effectiveness (added value) of tablet-based physiotherapy</td>
<td>H&amp;Y IG mean 2.57 (0.7)  CG mean 2.54 (0.7)  DD (y)</td>
<td>Total n = 230  IG n = 93  CG n = 137</td>
<td>Prospective controlled study 9 months</td>
<td>Primary outcome -QoL (PDQ-8)  Secondary outcomes -Participation restrictions (IMET) -Fear of falling (FES-I) -Sleep disorder (PDSS) –Anxiety/Depression (PHQ-4) -Comorobidity (SCQ-D) -Pain single item -Performance capability -Physical activity (Federal Health survey)</td>
<td></td>
<td>Innovations Fond Funding Programme of the federal Joint Committee, Project DEAL ⚫⚫⚫</td>
<td></td>
</tr>
<tr>
<td>Chen et al. (2021)</td>
<td>2 weeks MR</td>
<td>Effect of PD subtypes on efficacy MIR</td>
<td>H&amp;Y PIGD group 3.0 (1.0)  TD group 2.0 (1.0)  Indeterminate group 2.5 (1.0)  DD (y)</td>
<td>Total n = 49  PIGD n = 16  TD n = 19  Indeterminate group n = 14</td>
<td>Prospective open label study 2 weeks (discharge)</td>
<td>Primary outcome -motor performance (UPDRS-III)  Secondary outcomes -Balance (BBS) -mobility (TUG, 10MT, 6MWD, M-PAS) -Strength (5xSTS)</td>
<td></td>
<td>National Key research and Development Program Sub-project and the start-up fund for scientific research Talents of Beijing Rehabilitation Hospital, Capital Medical University of China ⚫⚫⚫</td>
<td></td>
</tr>
<tr>
<td>Study Authors</td>
<td>Intervention Duration</td>
<td>Type of Intervention</td>
<td>H&amp;Y</td>
<td>Outcome Measures</td>
<td>n</td>
<td>Study Duration</td>
<td>Results</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
<td>-----</td>
<td>----------------------------------------------------------------------------------</td>
<td>----</td>
<td>----------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Lo Buono et al. (2021) | 8 weeks MR            | Changes in anxiety and depression and quality of life | H&Y Median 3 (2.5-3) | DD Mean 8.5 (5.3) | Cognition (MoCA) mean 22.5 (4.6) | 100 | Prospective open label study | 60 days | Outcome - motor performance (UPDRS-III)  
|                       |                       |                      |     | ADL functioning (BI)                                                                |    |                | Italian department of Health                                             |
|                       |                       |                      |     | neuropsychological function/cognition (ACE-R)                                       |    |                |                                                                          |
|                       |                       |                      |     | depression (BDI-II)                                                                 |    |                |                                                                          |
|                       |                       |                      |     | Anxiety (HAMA-A)                                                                   |    |                |                                                                          |
|                       |                       |                      |     | QoL (PDQ-39)                                                                       |    |                |                                                                          |
|                       |                       |                      |     | speech language (Clinical Beside Swallowing examinations, Robertson dysarthria profile) |    |                |                                                                          |
| Scherbaum et al. (2020)| 2 weeks MR           | Effectiveness of PD-MCT midterm outcome and QoL. | H&Y Median 3 (2.5-3) | DD Mean 8.5 (5.3) | Cognition (MoCA) mean 22.5 (4.6) | 47  | Prospective open label study | 6 weeks | Effectiveness of PD-MCT mid-term outcome and QoL.  
|                       |                       |                      |     | Outcome - QoL (PDQ-39 and EuroQol)                                                |    |                | Deutsche Parkinson Vereinigung Bundesverband                              |
|                       |                       |                      |     | Secondary outcomes - Motor function (MDS-UPDRS-III, TUG and PPT)                   |    |                |                                                                          |
|                       |                       |                      |     | - Depression (BDI-II)                                                              |    |                |                                                                          |
|                       |                       |                      |     | - Global change (PGIC)                                                             |    |                |                                                                          |
| Hartelt et al. (2020) | 2 weeks MIR          | Effect of PD-MCT on motor symptoms and motor complications | H&Y Median 3 (2.5-3) | DD Mean 8.5 (5.3) | Cognition (MoCA) mean 22.5 (4.6) | 47  | Prospective open label study | 8 weeks | Effect of PD-MCT on motor symptoms and motor complications.  
|                       |                       |                      |     | Outcomes - motor assessment (MDS-UPDRS-II, III, IV, TUG, BBS, PPT)                 |    |                | Deutsche Parkinson Vereinigung Bundesverband                              |
|                       |                       |                      |     | - non-motor assessment (MDS-UPDRS-I, BDI-II, AES-D, HAMD-17)                      |    |                |                                                                          |
| Nielsen et al. (2020) | 2 weeks MIR          | Effect on mobility, physical function, and health related quality of life (HRQoL) | H&Y Total 2.1 (SD 1.1) | Center 1/ CST 2.1 (SD 0.7) | Center 2/VRC 2.2 (SD 0.7) | Total 7.5 (SD 4.2) | Cognition ? | Total n = 214 | Two centers involved | PDQ-39 (only) | Prospective open label study | 4 months, 10 months | Primary outcome - QoL (PDQ39)  
|                       |                       |                      |     | - Handgrip strength, - motor (TUG), - Anxiety/ Depression (HADS), - Falls (FES-I) |    |                | SANO: Center for Health and Rehabilitation, Danish Association for Rheumatism, Copenhagen Denmark Danish Parkinson’s Association |

(Continued)
<table>
<thead>
<tr>
<th>Author [ref]</th>
<th>Intervention and duration</th>
<th>Objective</th>
<th>Disease severity</th>
<th>Subjects (n)</th>
<th>Study design</th>
<th>Duration follow-up (from baseline)</th>
<th>Primary- and Secondary endpoints</th>
<th>Funding</th>
<th>GRADE (Quality of evidence)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Retrospective studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Krause et al. (2022) [52]</td>
<td>3 weeks MIR</td>
<td>Effect on motor and non-motor symptoms, and QoL</td>
<td>H&amp;Y Total H&amp;Y Mean 2.55 (0.7) DD (y) Mean 10.8 (7.9) Cognition (Mini-mental state-MMST) mean 28.66 (2.11)</td>
<td>Total n = 143 3 G n = 70 2 G n = 73</td>
<td>Retrospective study</td>
<td>3 weeks (discharge)</td>
<td>Outcomes - motor-performance (UPDRS-III) - psychosocial function (scopa-ps) - Depression (BDI) - QoL (PDQ^39, SF36) - Sleep (PDSS, ESS) - Impulsiveness (Quip) - Apathy (SAS) - change in medication - Balance (BBS) - mobility (TUG, MSST)) - Strength (StSt)</td>
<td>Projekt DEAL, German research foundation (DFG)</td>
<td>⊕ ⊕ ⃝ ⃝</td>
</tr>
<tr>
<td>Michels et al. (2022) [53]</td>
<td>3 weeks MR</td>
<td>Effect of PKB on motor abilities, cognitive profiles and reported depressive symptoms and psychosocial functioning.</td>
<td>H&amp;Y mean 2.78 (0.67) DD (y) mean 108.67 months (74.76) ≈ 9.06 y Cognition MMSE 27.53 (2.8) MoCA 24.0 (4.6)</td>
<td>n = 40</td>
<td>Retrospective study</td>
<td>3 weeks (discharge)</td>
<td>Outcomes - motor performance (UPDRS-III) - Cognition (MMSE, MoCA) - Attention (TAP, TMT-A) - Memory (WMS-R, VLMT, MCGCF) - visuospatial function (MCGCF, CORSI) - language (CERAD+, Boston naming test) - executive function (WMS-R, RWT, TMT-B) - neuropsychological tests (BDI-II, scopa-ps)</td>
<td>Not applicable</td>
<td>⊕ ⊕ ⃝ ⃝</td>
</tr>
<tr>
<td>Study</td>
<td>Duration</td>
<td>Design</td>
<td>H&amp;Y</td>
<td>Cognition</td>
<td>Total</td>
<td>Retrospective</td>
<td>Outcomes</td>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>--------</td>
<td>-----</td>
<td>----------</td>
<td>-------</td>
<td>---------------</td>
<td>----------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Ziegler et al. (2022) [54]</td>
<td>2 weeks MR</td>
<td>Effect of PD-MCT and identify predictors concerning ADL disability.</td>
<td>H&amp;Y Not mentioned (disease severity ICD classification) DD (y) Not mentioned Cognition (MoCA) mean 19.9 (4.7)</td>
<td>$n = 591$</td>
<td>Retrospective study, 6 weeks</td>
<td>Primary outcome - ADL (UPDRS-II) Secondary predictors: Basic parameters - age - gender - baseline ADL (UPDRS-II) - baseline motor score (UPDRS-III) - comorbidity</td>
<td>Deutsche Parkinson Vereinigung (DPV) and the Deutsche Stiftung Neurologie (DSN).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heinrich et al. (2021) [17]</td>
<td>7-21 days MR</td>
<td>PD-MCT to identify predictors of motor improvement and long-term dynamics of health-related quality of life (HR-QoL)</td>
<td>H&amp;Y Median 3.0 (2.5-4.0) DD (y) Mean 9.4 (6.3) Cognition (MoCA) mean 19.9 (4.7)</td>
<td>Total $n = 159$ PD $n = 134$ APS $n = 25$</td>
<td>Retrospective study 1 months (Telephone interview) 12 months (only SF-12)</td>
<td>Outcomes - motor performance (UPDRS-III, Tinetti test) - changes medication (LEDD) - HR QoL (SF-12) * Baseline - non-motor symptoms (NMSQ) Depression (HADS-D, BDI-II) - Cognition (MoCA)</td>
<td>Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Interdisciplinary Center of Clinical Research of the Medical Faculty of Jena and a grant from Bundesministerium fur Bildung und Forschung (BMBF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meloni et al. (2021) [55]</td>
<td>3-4 weeks MR</td>
<td>Effect on functional, cognitive, and geriatric domains</td>
<td>H&amp;Y Total mean 3.88 (SD 0.91) Mild-moderate group $n = 10$ Severe stage group $n = 14$ DD (y) Mean 10.43 (SD 6.15) Cognition (MMSE) Baseline 24.79 (SD 5.82)</td>
<td>$n = 24$ Mild-moderate group $n = 10$ Severe stage group $n = 14$</td>
<td>Retrospective study, 3-4 weeks (discharge)</td>
<td>Outcomes - Functional performance (BI) - cognition (MMSE, Token test, Phonemic and Semantic fluency, Copy and Recall Rey’s Figure, Ravens Colored Progressive Matrices) - geriatric domains (Numeric Rating scale, Norton scale, Conley scale)</td>
<td>Italian Ministry of Health Ricerca Corrente: RIN network</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Author</th>
<th>Intervention and duration</th>
<th>Objective</th>
<th>Disease severity</th>
<th>Subjects (n)</th>
<th>Study design</th>
<th>Duration follow-up (from baseline)</th>
<th>Primary- and Secondary endpoints</th>
<th>Funding</th>
<th>GRADE (Quality of evidence)</th>
</tr>
</thead>
<tbody>
<tr>
<td>II. Non-MR interventions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jäggii et al. (2023) [56]</td>
<td>2-4 weeks</td>
<td>Exergame (Dividat Senso) rehabilitation, integrated into rehabilitation program</td>
<td>H&amp;Y IG median 3</td>
<td>Total n = 40; IG n = 19</td>
<td>Randomized, placebo controlled study</td>
<td>2-4 weeks (discharge)</td>
<td>Primary outcomes: Feasibility of the training, adherence rate, attrition rate, AE, experience questions (SUS), enjoyment (NASA-TLX), Secondary outcomes: Cognitive (Go/No-Go test, color word interference test (D-KEFS), Motor (Reaction Time RTT, preferred-, maximum- and dual task- gait speed, physical performance (SPPB), walking (TUG, 5xStS, TMT)</td>
<td>Swiss Federal Institute of Technology Zurich</td>
<td>⊕⊕⊕ ⃝</td>
</tr>
<tr>
<td>Raciti et al. (2022) [57]</td>
<td>8 weeks</td>
<td>robotic therapy with an exoskeleton (ArmeoSpring/Hocoma Inc, Zurich)</td>
<td>H&amp;Y IG median 2 (2-3)</td>
<td>Total n = 24; IG n = 15</td>
<td>Single-blinded, randomized placebo-controlled study</td>
<td>8 weeks (discharge)</td>
<td>Primary outcome: Functional performance (9HPT), Secondary outcomes: Motor performance (UPDRS-III, MI-UE, FMA-UE), Functional performance (FIM), Pain (P-NRS)</td>
<td>No external funding</td>
<td>⊕⊕ ⊕○</td>
</tr>
</tbody>
</table>
Goosses et al. (2020) [58] 8 days Music-Assisted Treadmill Training (MATT) Feasibility and effect of the MATT program on motor- and cognitive functions, mood, fatigue and QoL H&Y IG median 2.5 (R = 1.5) CG median 2.5 (R = 1.5) DD Mean 8.63 (6.60) IG 8.64 (5.49) CG 6.94 (4.25) Cognition (MoCA) 25 for both groups Total n = 32 Randomized controlled study 8 days 6-weeks (telephone interview) Outcomes - Pat subjective training perception - acceptance/feasibility of the therapy (Likert scale) - Cognition (MoCA, TAP, WMSR, UPSDRS-IV+) - Motor function (UPDRS-III, FOG) - Functional integrity of lower extremity walking, balance, gross and fine hand function, - EOG - Mood (GDS) - QoL (PDQ-39) - Fatigue (PSF-16) - Functional (FIM) Budget resource of the participating study sites. The Galitainer 3 was sponsored by Biodex Medical systems Inc

Zhu et al. (2020) [59] 12 week Tai Chi (+outpatient) Effect of Tai Chi on motor and non-motor symptoms H&Y IG mean 2 (2.2) CG mean 2 (1.2) DD IG mean 4.68 (0.43) CG mean 4.00 (0.39) Cognition (MoCA) IG mean 21.37 (2.52) CG mean 22.05 (2.78) Total n = 41 Randomized placebo-controlled study 12 weeks Primary outcome - Motor performance (UPDRS-III, BBS) Secondary outcomes Non-motor - sleep quality (PDSS) - depression (HAMD) - anxiety state (HAMA) - cognitive function (MoCA) - quality of life (PDQ-39), Project of Science Technology Department of Zhejiang Province

De Luca et al. (2020) [60] 8-week music assisted therapy (inpatient) Effect on non-motor symptoms H&Y Total n = 40 Cross-sectional controlled study 8 weeks (discharge) Outcomes - psychological (PGWBI) - QoL (HRQoL) - Coping (Brief-COPE) - motor performance (FIM, TUG, 10mWT) No external funding

(Continued)
<table>
<thead>
<tr>
<th>Author [ref]</th>
<th>Intervention and duration</th>
<th>Objective Disease severity -H&amp;Y -DD (y)</th>
<th>Subjects (n)</th>
<th>Study design</th>
<th>Duration follow-up (from baseline)</th>
<th>Primary- and Secondary endpoints</th>
<th>Funding</th>
<th>GRADE (Quality of evidence)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brognara et al. (2020) [61]</td>
<td>Single mechanical stimulation by wearing insoles during 5 min</td>
<td>Effect of foot plantar stimulation on gait parameters</td>
<td>H&amp;Y Mean not mentioned DD Mean not mentioned (residential profile) Cognition ?</td>
<td>Total n = 24 IG n = 12 CG n = 12</td>
<td>Cross-sectional controlled study</td>
<td>30 minutes</td>
<td>No external funding</td>
<td>⊕⃝⃝⃝</td>
</tr>
<tr>
<td>Gassner et al. (2023) [62]</td>
<td>4-week inpatient therapeutic climbing</td>
<td>Feasibility of therapeutic climbing integrated in rehabilitation and effect on gait</td>
<td>H&amp;Y tot mean 1.92 H&amp;Y1 16% (n = 4) H&amp;Y2 68% (n = 17) H&amp;Y3 (n = 4) DD (y) mean 7 (1-23) Cognition Not mentioned</td>
<td>n = 26</td>
<td>Prospective feasibility study</td>
<td>4 weeks (discharge)</td>
<td>Primary outcome - Self-perceived differences in health and well-being (survey; no validation of survey) Secondary outcomes - 10MWT - Functional Gait Assessment - 2MWT - TAT - 9-HPT</td>
<td>Hilde-Ulrichs Foundation for Parkinson research</td>
</tr>
<tr>
<td>Brandin-De la Cruz et al. (2020) [63]</td>
<td>4-week virtual reality and antigravity treadmill training</td>
<td>Feasibility and efficacy of mechanical gait assistance combined with virtual reality</td>
<td>H&amp;Y Mean 2.03 DD (y) Mean not mentioned Cognition Not mentioned</td>
<td>n = 12</td>
<td>Prospective feasibility study</td>
<td>4 weeks (discharge)</td>
<td>Primary outcome -Motor performance (6MWT) Secondary outcomes - Gait speed (10MWT), - Balance (Tinetti scale), - QoL (SF-36)</td>
<td>Not mentioned</td>
</tr>
</tbody>
</table>
### Retrospective studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Effect of BWSOGT on functional and motor performance</th>
<th>Total n = 37</th>
<th>Retrospective case-controlled study</th>
<th>Outcomes</th>
<th>No specific funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koyanagi et al. (2021) [64]</td>
<td>4-week body weight-supported overground gait training (BWSOGT)</td>
<td>IG n = 19</td>
<td>4 weeks (discharge)</td>
<td>- Functional performance (UPDRS-II)</td>
<td>⊕⊕⊕ ⊕</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CG n = 18</td>
<td></td>
<td>- Motor performance (UPDRS-III, 10-MWT, Velocity, stride length, 6-MWT, TUG, BBS, and FOG)</td>
<td>⊕⊕⃝ ⃝</td>
</tr>
</tbody>
</table>

**ADL**, activities of daily living; APS, Atypical Parkinsonism; CBF, Cerebral blood flow; CG, Control group; DD, Disease duration; fALFF, fractional amplitude of low-frequency; FOG, freezing of gait; HC, healthy controls; IG, Intervention group; MR, multidisciplinary rehabilitation; PIGD, postural instability and gait difficulty-predominant disease; QoL, Quality of Life; Resting state BOLD, blood oxygen level dependent; Resting-state ASL, arterial spin labelling; Resting-state BOLD scan, blood oxygen level-dependent; TD, tremor dominant; UMCG, University Medical Center Groningen.

**Scales/tests**: ACE-R, Addenbrooke’s Cognitive Examination-Revised; AES-D, Apathy Evaluation Scale; ALDS, AMC Linear Disability scale; BI, Barthel Index; BBS, Berg-Balance Scale; BDI, Beck depression inventory; Brief-COPE, Brief coping orientation in problems experiences; CIBIAD+, Consortium to Establish a Registry for Alzheimer’s Disease-Plus; Conley scale, assess the fall risk; CORSI, block tapping; D-KEFS, Delis–Kaplan Executive Function System; FES-I, Falls Efficacy Scale—international; FIM, Functional Independence Measure; FMA-UE, Fugl-Meyer Assessment for the upper extremity; FTSTS, 5-times sit to stand test; GDS, Geriatric Depression Scale; HADS, Hospital Anxiety and Depression Scale; HAMA-A, Hamilton Anxiety Rating Scale; HAMD, Hamilton rating scale for depression; 9-HPT, 9 hole Peg test; HRQoL, Health related Quality of life; IMET, Index zur Messung von Einschränkungen der Teilhabe (Measurement of Restrictions on Participation); LPS50+, Leistungsprüfsystem (cognition); MCGCF, Medical College of Georgia Complex Figures; MI-UE, Motricity Index for Upper Extremity; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; MMST, Mini Mental State; M-PAS, Modified Parkinson activity scale; MSST, Minute-Sit-to-Stand-Test; 6MT and 10MT test, 6 and 10 meter walk test; 6MWD test, 6 min walk distance test; NASA-TLX, Task load index; NMSQ, non-motor symptoms Questionnaire; Norton scale, risk of contracting pressure ulcers; NPI, Neuropsychiatric Inventory; PDSS, Parkinson’s disease sleeping scale; PSF, Parkinson Fatigue Scale; Quip, Questionnaire for Impulsive-compulsive Disorders in PD; RBT, Reaction Time Test; RWT, Regensburger Wortflüssigkeitstest; SAS, Starkstein Apathy scale; SCOPA, Scales for Outcome in Parkinson’s Disease; SCOPA-SPES, short Parkinson’s disease evaluation scale; SCOPA-COG, COGnition; SCOPA-PS, PsychoSocial; SCDO-D, Self-Administered Comorbidity Questionnaire; SF 36 and SF-12, Short form health survey; SPPB, Short physical performance battery; 5xStS, 5 times Sit-to-Stand; SUS, system usability scale; TAP, Test of Attentional Performance; TAT, Tinetti Assessment Tool; TMT-A, Trail making test; TUG, Timed up and go test; UPDRS-I-IV, Unified Parkinson’s disease rating scale; VLM, Verbal Learning and memory test; WMS-R, Weschler Memory Scale revised; Assessment by GRADE (imprecision, inconsistency, indirectness, and publication bias), may affect the confidence in the results: ⊕⊕⊕ High: We are very confident that the true effect lies close to that of the estimate of the effect. ⊕⊕⃝ Moderate: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.⊕⃝⃝ Very low: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. ⊕⊕⃝ Low: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
The short-term motor improvement in the controlled MR group varied between 17–19% [47–49]. Short-term motor improvement in the open label MR group varied between 13–30% [14, 15, 22, 50, 51]. Only 1 controlled MR study reported long-term change of motor scores, which worsened 2% after 2 years vs. baseline [47]. Long-term motor effects in the open label MR group varied from 16–17% [14, 15, 51].

The short-term motor scores of the controlled non-MR interventions varied from 8–26% [56, 57, 59, 60], whereas the open label studies varied from 15-65% [62, 63] in their overall motor scores. None of the non-MR interventions described long-term effects.

Functional improvement

Functional improvement was only measured in 10 out of 22 studies (5 studies in the MR group [15, 47, 50, 54, 55] and 5 in the non-MR group [56, 57, 62–64], see Tables 2 and 3) and was measured by a great variety of tests including the UPDRS-II, Barthel index, SF-36, 9HPT, and 10MWT.

Short-term outcome in the MR group improved in one controlled study with 18% [47], in two open label studies with 14% [15] and 31% [50]. Long-term effects in the MR group were measured in two studies. One controlled study reported an improvement of 6% after 2 years [47] and one open label study showed an improvement of 2.6% after 8 weeks [15].

Short-term effects in the controlled non-MR group were reported in two studies, both showing a score of 19% [56, 57]. In the prospective open label non-MR group functional outcome varied from 13–25% [62, 63]. None of the non-MR interventions described long-term effects on functional scales.

Improvement in cognition

Only 7 studies; 5 in the MR group [47, 50, 52, 53, 55] and 2 in the non-MR [56, 59] (Table 2) measured cognitive function, using different tests including MMSE, SCOPA-COG, MMST, MoCA, Go/no go, and D-KEFS.

Short-term cognitive improvement was seen in 4 studies within the MR group (Table 3); 27% in a controlled study [47], 4% in a non-controlled study [50] and only 1% in a retrospective study [52]. One retrospective study showed 1.5% worsening of cognition [53]. One controlled study in the MR group showed 9% worsening of cognition after 2 years, which was not significantly different vs. baseline [47].

Two RCTs in the non-MR group showed short-term cognitive improvement of 12% [56] and 5% [59]. None of the non-MR interventions described long-term effects on cognition.

Quality of life

Quality of life was assessed in 6 studies of the MR group [14, 17, 49–52] and in 2 studies of the non-MR group [59, 63], measured by PDQ-8, PDQ-39, SF-12, and SF-36 (Table 2).

Short-term improvement of QoL in the controlled MR group was 9% [49] and varied between 7–30% in the open label MR group [14, 50, 51]. Long-term data on QoL in 1 controlled study within the MR group [49], whereas 1 open label study showed stable QoL measures over 10 months [51].

The non-MR data showed significant short-term QoL improvement in 1 RCT of 5% [59], vs. 20% improvement in a controlled trial [60]. The open label non-MR studies showed 25–54% improvement of QoL [63]. No long-term data on QoL were reported in any of the non-MR interventions.

Medication changes

Although an optimal medication regimen is very important to support PwPD, not all interventions included medication optimization as an endpoint. LEDD changes were only registered in 6 studies [17, 47, 48, 52, 53, 55] of the MR group (Table 2) Two controlled studies [47, 48] showed a LEDD increase of 45% [47] and an unchanged LEDD [48]. Three non-controlled studies [17, 52, 53] showed an increase in between 7.5- and 18%. One retrospective study [55] showed a decrease in LEDD of 11%.

The non-MR group contained 4 studies [56, 57, 62, 64] which reported pre-and post test doses of dopaminergic drugs (LEDD). However, in 3 studies the LEDD was kept stable during the intervention, in order to differentiate between medication effects and the effects of the intervention [57, 62, 64].

Cost-effectiveness

Only 1 study [47] assessed the costs of the MR intervention and the outpatient follow-up. The inpatient costs were 12,500 € for about 6 weeks in the clinic, whereas the costs of the follow-up, including extra paramedical support were 4,000 €/3 months, resulting in total costs of 44,500 €/patient over 2-years in the intervention group, compared to 180,000
Table 3
Percentage improvement in motor, functional, cognition and quality of life and medication changes/optimization (LEDD in mg) in multidisciplinary interventions and non-multidisciplinary interventions. Short-term effects are expressed as % improvement vs. baseline. Most studies did not report long term effects, whereas the duration of follow-up showed significant variation.

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Follow-up</th>
<th>Motor score</th>
<th>ADL</th>
<th>Cognitive</th>
<th>Quality of Life</th>
<th>Dopaminergic medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term (non-randomized)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steendam-Oldekamp and T. van Laar (2022) [17]</td>
<td>3 years</td>
<td>19%</td>
<td>-2%</td>
<td>SCOPA-</td>
<td>-2%</td>
<td>-</td>
</tr>
<tr>
<td>Li (2023) [40]</td>
<td>2 weeks</td>
<td>17%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Wagner (2022) [40]</td>
<td>9 weeks</td>
<td>15%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chen (2021) [22]</td>
<td>2 weeks</td>
<td>16%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Le Beau (2021) [56]</td>
<td>8 weeks</td>
<td>16%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Schoonhoven (2020) [14]</td>
<td>6 weeks</td>
<td>13%</td>
<td>18%</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Harkki (2020) [15]</td>
<td>8 weeks</td>
<td>13%</td>
<td>18%</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nilsen (2020) [31]</td>
<td>10 months</td>
<td>14%</td>
<td>17%</td>
<td>UPDRS-III</td>
<td>14%</td>
<td>2.2%</td>
</tr>
<tr>
<td>Reptacular studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kvaara (2019) [52]</td>
<td>5 weeks</td>
<td>23%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Michalski (2019) [53]</td>
<td>3 weeks</td>
<td>27%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Eggert (2019) [34]</td>
<td>6 weeks</td>
<td>-</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Harkki (2018) [57]</td>
<td>12 months</td>
<td>28%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Meliss (2019) [58]</td>
<td>3 weeks</td>
<td>-</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mangini (2021) [59]</td>
<td>2 weeks</td>
<td>23%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gassiot (2020) [50]</td>
<td>8 weeks</td>
<td>12%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>On Laar (2020) [60]</td>
<td>3 days</td>
<td>12%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Brogdon (2021) [61]</td>
<td>7 days</td>
<td>-</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gassiot (2022) [62]</td>
<td>4 weeks</td>
<td>15%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Brandis-On Bro (2021) [63]</td>
<td>7 weeks</td>
<td>15%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kovace (2021) [64]</td>
<td>4 weeks</td>
<td>20%</td>
<td>-</td>
<td>UPDRS-III</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
| Table 3: Percentage improvement in motor, functional, cognition and quality of life and medication changes/optimization (LEDD in mg) in multidisciplinary interventions and non-multidisciplinary interventions. Short-term effects are expressed as % improvement vs. baseline. Most studies did not report long term effects, whereas the duration of follow-up showed significant variation.

DISCUSSION

This review focused on 22 inpatient rehabilitation studies published in the last 3 years, 13 studies based on a multidisciplinary approach in rehabilitation centers or hospitals. This many studies in only 3 years shows the interest in the field. However, only 9 studies were performed with control groups, from which only 4 studies were randomized, only in the non-multidisciplinary field. This resulted in an overall rather poor GRADE rating, with only 6 studies reaching a moderate grade, no studies with a high grade and most studies having a low or even very low grade.

Previous recommendations of 20 expert centers in multidisciplinary PD care [66] indicated that an outpatient setting is the preferred way to organize care for most PD patients. However, an inpatient setting is the preferred way to perform PD rehabilitation, especially if multidisciplinary care is needed [21], people are about to lose their independence [47], or need to be treated with advanced therapies [66]. The final success of inpatient rehabilitation is highly dependent from proper communication with the involved outpatient (allied) healthcare professionals [47, 49]. For instance, a higher frequency of visits of the general physician was significantly associated with longer survival time, fewer inpatient days, and lower health care costs [67].

The issue of suboptimal medication regimens is very important. Suboptimal medication leads to impaired ADL and reduced QOL, and to unnecessary neuropsychiatric symptoms. Collaboration between pharmacists and physicians during all stages of the rehabilitation process therefore is required and beneficial [68, 69].

Strengths and limitations

Most of the included studies are no RCT studies, which is a risk for bias. PwPD with cognitive decline and/or co-morbidity were mostly excluded from the trials, whereas most trials included only PwPD in early H&Y stages (H&Y 1-3), with a relative short disease duration. So a significant proportion of PwPD were not represented by these studies [33, 70].

Some trials reported significant numbers lost to follow-up, even up to 20% or more, which implies an great risk on selection bias [71]. However, it...
is good to realize that the review period overlapped with the COVID-19 pandemic, which might have contributed to less favorable continuation rates [72].

The lack of sustained benefit and long-term data is a major criticism of most multidisciplinary interventions included in this overview. The major limitation to compare all included studies properly was the huge diversity in endpoints. We have tried to overcome this issue, using percentages of change. However, the same percentage change of different scales may not represent the same magnitude of improvement, due to the metrics of the scale. Also the rather short follow-up periods, and the limited information on medication changes over time, have strongly limited the value and long-term impact of our conclusions.

Last but not least, this dataset showed a serious lack of functional data, which is quite astonishing talking about rehabilitation programs. Only 10 out of 22 studies reported a functional outcome, and just 9 studies included a QoL measure. Despite the suggestions made in previous reviews and meta-analyses, almost nothing has changed in the methodology and design of rehabilitation trials over the last years. Researchers have continued in the same vein, resulting in the same weak recommendations.

Conclusions

The 6 moderate grade studies permit some conclusions, which might benefit the field. The only long-term controlled multidisciplinary study [47] clearly showed that a focused inpatient program including medication optimization [69], followed by an intensive outpatient program, was able to keep PwPD stable for 2 years, whereas a matched control group all stayed in the nursing home. This means that focused PD rehabilitation, including medication optimization with advanced therapies like L-dopa- and apomorphine infusions if indicated, is able to postpone definite nursing home admission with years, resulting in a huge improvement of ADL and with a significant cost reduction at the same time. The short-term controlled MR study with intensive PD rehabilitation [48] confirmed these positive effects of focused PD rehabilitation. Finally, the controlled non-MR studies indicate that exergaming, treadmill training, Taichi and exoskeleton-supported PD rehabilitation seem to be effective interventions or add-ons to existing PD rehabilitation programs, at least on the short-term. However, no long-term data on any of these new interventions were reported.

Future perspectives

This review also makes clear that RCTs are perhaps not the best way to evaluate the structure and efficacy of rehabilitation models, because of the highly variable modes of intervention. RCTs are also difficult to execute if PwPD have cognitive pathology, which was the reason they had been excluded from almost all trials described above. As a result, it is hard to say if the current results can be applied in more vulnerable population of PwPD, having cognitive and behavioral problems [33, 70].

So, it is really time to harmonize the design of rehabilitation trials with PwPD, including bigger and broader populations, with a longer duration of follow-up and standardized endpoints, including functional measures, which are less dependent from the cognitive abilities of the participants [70, 73–75].

Finally, new objectives and new endpoints should be introduced in future PD rehabilitation trials, using recent insights in the pathophysiology and subtyping of PD. Thus, modulating the gut’s microbiome by diets, pre- and probiotics, (potentially) disease modifying drugs, anaerobic exercise and/or lifestyle changes constitute interesting new objectives to integrate in new trial designs. Biomarkers might be integrated in new study designs to tailor a personalized approach to rehabilitation, termed “rehabilomics” [76, 77]. Aerobic exercise, including high intensity training, in early PD has shown to increase the aerobic capacity, endurance, and seems to slow down the progression of motor symptoms [78, 79]. Exercise paradigms, incorporating both goal-based practice and aerobic training might work synergistically to promote neuroplasticity. Another approach is to look at dual task practices, without aerobic exercise, which provides insight into the role of cognitive motor training, without the exercise component [80, 81]. Preliminary data indicate an association between effective rehabilitation and brain reorganization, with restoration of the cortico–subcortical pathway and activation of compensatory networks, e.g., the frontoparietal networks [82, 83]. These approaches indicate a possible role of targeted rehabilitation in disease modification [48]. Finally, future trials should implement telehealth and wearables. Providing telehealth to participants exercising at home has proven to be substantially more time efficient for the physiotherapist, compared to center-based classes [84]. Participants identified a variety of benefits, including the reduction of financial- and travel-related burdens [85]. Digitalization and
increased connectivity and the expanding capabilities of sensors will allow that more care can be given at home [86]. Artificial intelligence can be helpful to remotely assess the motor performance of PwPD. Finger-tapping is commonly used in neurological exams to evaluate bradykinesia. A recent study [87] developed computer algorithms to obtain objective measurements obtained from PwPD sitting in front of a webcam, that aligned with the MDS-UPDRS guideline, which proved to be strongly correlated with the neurologists’ ratings.

ACKNOWLEDGMENTS

The authors have no acknowledgments to report.

FUNDING

The authors have no funding to report.

CONFLICT OF INTEREST

ESO has no conflict of interest to report. TVL reports consultancy: AbbVie, Britannia Pharm, Clexio; Grants: MJFF, Dutch Brain Foundation, UMCG, Parkinson NL and honoraria: AbbVie, Centrapharm, Britannia Pharm., Eurocept, Genilec, all outside the submitted work.

DATA AVAILABILITY

Data is available on request from the corresponding author.

REFERENCES


